| Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals C Kim, V Prasad JAMA internal medicine 175 (12), 1992-1994, 2015 | 409 | 2015 |
| The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses V Prasad, C Kim, M Burotto, A Vandross JAMA internal medicine 175 (8), 1389-1398, 2015 | 376 | 2015 |
| Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study G Giaccone, C Kim, J Thompson, C McGuire, B Kallakury, JJ Chahine, ... The Lancet Oncology 19 (3), 347-355, 2018 | 350 | 2018 |
| Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review MR Cook, C Kim JAMA oncology 5 (7), 1049-1054, 2019 | 208 | 2019 |
| Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis DH Kim, C Kim, EL Ding, MK Townsend, LA Lipsitz Hypertension 62 (1), 27-32, 2013 | 198 | 2013 |
| Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs C Kim, V Prasad Mayo Clinic Proceedings 91 (6), 713-725, 2016 | 127 | 2016 |
| Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection NJ Shah, G Al-Shbool, M Blackburn, M Cook, A Belouali, SV Liu, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 114 | 2019 |
| Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer N Roper, AL Brown, JS Wei, S Pack, C Trindade, C Kim, O Restifo, S Gao, ... Cell reports medicine 1 (1), 2020 | 112 | 2020 |
| Role of local ablative therapy in patients with oligometastatic and oligoprogressive non–small cell lung cancer C Kim, CD Hoang, AH Kesarwala, DS Schrump, U Guha, A Rajan Journal of Thoracic Oncology 12 (2), 179-193, 2017 | 101 | 2017 |
| Characterization of KRAS mutation subtypes in non–small cell lung cancer J Judd, N Abdel Karim, H Khan, AR Naqash, Y Baca, J Xiu, ... Molecular cancer therapeutics 20 (12), 2577-2584, 2021 | 98 | 2021 |
| MEK inhibitors under development for treatment of non-small-cell lung cancer C Kim, G Giaccone Expert opinion on investigational drugs 27 (1), 17-30, 2018 | 79 | 2018 |
| Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers A Rajan, C Kim, CR Heery, U Guha, JL Gulley Human vaccines & immunotherapeutics 12 (9), 2219-2231, 2016 | 76 | 2016 |
| LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid … SV Liu, LC Villaruz, VHF Lee, VW Zhu, CS Baik, A Sacher, CE McCoach, ... Annals of Oncology 31, S1189, 2020 | 75 | 2020 |
| Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes A Estrada-Bernal, AT Le, AE Doak, VG Tirunagaru, S Silva, MR Bull, ... Clinical Cancer Research 27 (5), 1463-1475, 2021 | 69 | 2021 |
| Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung C Kim, SV Liu, DS Subramaniam, T Torres, M Loda, G Esposito, ... Journal for immunotherapy of cancer 8 (2), 2020 | 58 | 2020 |
| Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies C Tlemsani, N Takahashi, L Pongor, VN Rajapakse, M Tyagi, X Wen, ... Science translational medicine 13 (578), eabc7488, 2021 | 52 | 2021 |
| Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up G Giaccone, C Kim Journal of Thoracic Oncology 16 (3), 483-485, 2021 | 49 | 2021 |
| Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature J Zaemes, C Kim European Journal of Cancer 132, 168-175, 2020 | 42 | 2020 |
| Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature C Kim, A Rajan, PA DeBrito, G Giaccone Translational lung cancer research 5 (6), 720, 2016 | 37 | 2016 |
| Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung E Dudnik, S Kareff, M Moskovitz, C Kim, SV Liu, A Lobachov, T Gottfried, ... Journal for ImmunoTherapy of Cancer 9 (2), 2021 | 33 | 2021 |
